Related Experiment Video
Updated: Mar 2, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Novel agents in mantle cell lymphoma
1a Department of Haematology , Derriford Hospital , Plymouth , UK.
Introduction:
Mantle cell lymphoma (MCL) usually takes an aggressive clinical course and carries a poor prognosis. Recently, progress has been made in the treatment of MCL including the development of a number of novel agents which target intracellular pathways and the extracellular microenvironment. These agents have transformed the landscape of available therapeutic options. Areas covered: The current literature on the novel agents which currently hold a licence for the treatment of MCL in the context of front-line therapy and in the relapsed/refractory setting is summarized. In addition, targeted therapies showing promise at an earlier stage of development will also be discussed. A literature search was performed using the terms 'mantle cell lymphoma', 'bortezomib', 'temsirolimus', 'lenalidomide', 'ibrutinib', 'novel agents', 'targeted molecular therapies' and derivations thereof. Expert commentary: In addition to improvements in immunochemotherapy, a succession of new molecular targets and corresponding drugs has revolutionised MCL therapy. The discovery of a novel agent which disrupts external signalling pathways through inhibition of Bruton's tyrosine kinase has been a particularly exciting breakthrough. The best way to sequence and combine these agents with existing regimens and how to overcome the problem of drug resistance represent new challenges in this rapidly developing field.
Insights
Novel targeted therapies have transformed mantle cell lymphoma (MCL) treatment, offering new hope for patients with this aggressive cancer. Research highlights licensed and emerging agents, including Bruton
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a historically poor prognosis.
- Recent advancements in targeted therapies have significantly improved treatment options for MCL.
- Novel agents target specific intracellular pathways and the tumor microenvironment.
Purpose of the Study:
- To summarize licensed novel agents for front-line and relapsed/refractory MCL treatment.
- To discuss promising targeted therapies in earlier stages of development.
- To provide an expert commentary on the evolving landscape of MCL therapeutics.
Main Methods:
- Literature search using terms like 'mantle cell lymphoma', 'bortezomib', 'ibrutinib', and 'targeted molecular therapies'.
- Review of current literature on licensed and investigational agents for MCL.
- Synthesis of findings to provide an expert perspective.
Main Results:
- Novel molecular targets and drugs have revolutionized MCL therapy beyond traditional immunochemotherapy.
- Targeted agents, including Bruton's tyrosine kinase inhibitors, represent a significant breakthrough.
- Several novel agents are now licensed for MCL treatment in various settings.
Conclusions:
- Targeted therapies have transformed MCL treatment, improving outcomes for patients.
- Optimizing the sequencing and combination of these agents presents new challenges.
- Overcoming drug resistance is a critical area for future research in MCL.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Differentiation of Common Myeloid Progenitor Cells
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Tumor Immunotherapy

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)